Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market & Industry Briefs

Executive Summary

Brief summaries of recent medtech market and industry developments. This month we cover recent device M&A, Medtronic and Nile Therapeutics' collaboration in heart failure, Neoprobe and Naviscan PET Systems' deal in cancer detection, and Qiagen and Epigenomics AG's collaboration in a blood test for colorectal cancer.

You may also be interested in...



Market & Industry Briefs

Brief summaries of recent medtech market and industry developments. This month we cover transcatheter valve news announced at ACC, Covidien's brain aneurysm device, NMT Medical closing shop, J&J's move to acquire Synthes and VisualSonics in vivo imaging technology for cancer.

Market & Industry Briefs

Brief summaries of recent medtech market and industry developments. This month we cover transcatheter valve news announced at ACC, Covidien's brain aneurysm device, NMT Medical closing shop, J&J's move to acquire Synthes and VisualSonics in vivo imaging technology for cancer.

Radiosurgery Branches Out

The convergence of advancing technology and the push for more effective, noninvasive cancer treatments is helping to build the perfect storm of innovation for the field of stereotactic radiosurgery. SRS allows high doses of precisely focused ablative energy to be delivered to targeted tissues with a minimum of damage to surrounding areas. It has been used for years to treat tumors in the head and neck, where patient movement can be effectively restrained with frames to protect healthy tissue. However, technological advances are now making the procedure more viable for tumors in other parts of the body, and that opens the door to treating cancers in the lung, prostate, breast, and beyond.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC143429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel